Phase I trial for the Prevention of Cytokine Release Syndrome (CRS) with Cyclosporine in Patients with Moderate COVID-19

  • STATUS
    Enrolling By Invitation
  • participants needed
    25
Send
Updated on 19 February 2024

Summary

Recruiting hospitalized patients within Penn Medicine

The purpose of this study is to determine if it is safe to take Cyclosporine for up to two weeks in patients who have COVID-19 infection. The reason this is important for people afflicted with the COVID-19 virus is that an over active immune system leading to cytokine release syndrome is thought to cause death in some patients. The long-term goal of this research is to learn if Cyclosporine can prevent or decrease the risk of cytokine release syndrome. 

Description

The research study is being conducted to learn why some people get very sick from COVID-19. This study will test whether some people make more immune responses in the blood, and that this is an overreaction to the virus. This reaction can actually lead to harm and cause more damage in the lungs, leading to more difficulty breathing. By volunteering to be on this study, you would be treated with Cyclosporine, a drug that suppresses the immune response. You would take the drug for up to 2 weeks, or until you are discharged from the hospital, whichever comes first. 

FAQ


Details
Condition COVID
Age 18years - 99years
Clinical Study Identifier04412785
Last Modified on19 February 2024

Eligibility

If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.